Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An international team of scientists has been shortlisted out of 134 applications spanning 41 countries.

cruk-awardProf Vincenzo Cerundolo, Director of the MRC Human Immunology Unit (Radcliffe Department of Medicine, University of Oxford), is one of 16 investigators in the shortlisted team, led by Prof Lindy Durrant from The University of Nottingham/Scancell Ltd. Their proposed project aims to investigate how personalised cancer vaccines might be used to eradicate tumours in the future.

Therapies designed to boost our body’s immune system have revolutionised the treatment of cancer. However, these treatments don’t work in all patients, or against all cancers. This is partially due to our limited understanding of how the immune system interacts with tumour cells, but also because currently available immune-boosting therapies – known as ‘cancer vaccines’ – only target a small number of antigenic peptides, often only triggering a weak response by our immune system.

Prof Vincenzo Cerundolo Prof Vincenzo Cerundolo In order to create better cancer vaccines, the team wants to screen a large number of tumour antigens and use machine learning tools to predict which of these would trigger a good immune response in individual patients with cancer. Meanwhile they will test and develop new and more efficient ways of delivering the treatment. Armed with this knowledge, the team will then test their ideas in investigator-initiated clinical studies – with a special focus on patients with head and neck cancer, pancreatic cancer, lung cancer and one type of brain tumour. This will allow the team to build templates for how to treat different cancers. If successful, these templates will allow doctors to easily identify which antigens to target, and then which type of vaccine to use, to create truly bespoke vaccines for each patient and radically improving survival on a global scale.

The Grand Challenge award aims to revolutionise how we diagnose, prevent and treat cancer by providing international multi-disciplinary teams the freedom to try novel approaches, at scale, in the pursuit of life changing discoveries. Prof Cerundolo’s team will receive seed-funding of up to £30,000 to draft their full research proposal, and the winning proposal will be announced in autumn 2018.

Similar stories

New study maps the development of the human intestine

MRC HIU RDM

Researchers in the Simmons lab chart the embryonic origins and appearance of diverse intestinal cellular compartments, with important implications for intestinal diseases.

MRC HIU appoints new Director

MRC HIU RDM

We are pleased to announce that Professor Alison Simmons has been appointed as the new Director of the MRC Human Immunology Unit.

Study uncovers how low blood iron diminishes immune response

MRC HIU NDM RDM

The Drakesmith group finds that low blood serum iron levels can inhibit T-cell and B-cell immune responses to vaccines and infections.

Interferon-b trial shows positive results

COVID-19 MRC HIU NDM

A trial of a new inhaled antiviral drug for COVID-19 has shown positive results and the drug is now moving into a larger international phase 3 trial of hospitalised patients. MRC HIU's Professor Ling-Pei Ho is one of the main co-authors on the paper.

Role-playing computer game helps players understand how vaccines work on a global scale

Centre for Computational Biology MRC HIU RDM

A free game launched today allows players to role-play the deployment of a virtual vaccine to help to halt the global spread of a viral pandemic.

Persistent immune memory of COVID-19 found in recovered patient T cells

COVID-19 MRC HIU NDM RDM

New Nature Immunology paper finds strong T cell responses in recovered COVID-19 patients